US EditionSMT's Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025
- A study enrolled 161 patients from 20 centers worldwide, including 18 centers from France, Germany, Spain, Denmark, and the UK.
- The results reveal a device success rate of about 97%, with an average operation time of 41.60 minutes, and 94.4% of patients show no above moderate tricuspid regurgitation .
- The TRINITY Trial's 6-month outcomes show good safety and performance, improving quality of life with a low rate of composite adverse events.
- Another study enrolled 114 patients from 18 centers in China, showing a 95% device success rate at 30 days and an average operation time of 67.53 minutes.
71 Articles
71 Articles
Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.
BEIJING, Oct. 29, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes…
SMT's Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025
Sahajanand Medical Technologies (SMT) announced significant new findings from four landmark clinical studies, namely TUXEDO II, Multivessel TALENT, Cruz Senior Study, and the SFlex Netherlands Registry, presented at the TCT 2025 conference. The collective data reinforces the proven safety, efficacy, and consistent performance of the Supraflex Cruz drug eluting stent (DES) across a broad spectrum of complex patient populations. Prof. …
SMT’s Supraflex Cruz shows consistent and robust clinical outcomes across key global studies
Sahajanand Medical Technologies (SMT) announced significant new findings from four landmark clinical studies, namely TUXEDO II, Multivessel TALENT, Cruz Senior Study, and the SFlex Netherlands Registry, presented at the TCT 2025 conference. The collective data reinforces the proven safety, efficacy, and consistent performance of the Supraflex Cruz drug eluting stent (DES) across a broad spectrum of complex patient populations. In the TUXEDO-II T…
Coverage Details
Bias Distribution
- 70% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
